Are there unique autoantigens triggering autoimmune diseases?
- 1 August 1998
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 164 (1) , 139-155
- https://doi.org/10.1111/j.1600-065x.1998.tb01216.x
Abstract
Using three reference disease models--insulin-dependent diabetes mellitus (IDDM) as a prototype of T-cell mediated organ-specific autoimmune disease, myasthenia gravis (MG) as a prototype of autoantibody-mediated organ-specific autoimmune disease and systemic lupus erythematosus (SLE) as a prototype of non-organ-specific autoimmune disease--we have reached several conclusions: 1) All three diseases are associated with the presence of multiple autoantibodies and/or autoreactive T cells that recognize a large number of antigenic molecules. The apparent predominant role of certain antibodies in some diseases could relate to their functional properties such as acetylcholine receptor (AChR) blockade for anti-AChR autoantibodies in MG or anti-dsDNA in SLE. 2) Major target antigens are clustered in the target cell affected by organ-specific autoimmune diseases: beta cells in IDDM, striated-muscle cells in MG, or apoptotic cells in the case of SLE. 3) Antibodies and T cells recognize multiple epitopes in these molecules. 4) The most evident explanation for the observed clustering and diversity is autoantigen spreading. Spreading probably involves T cells secreting proinflammatory cytokines but also possibly antibodies as in the case of nucleosome autoantibodies in SLE. 5) The counterpart of antigen spreading is bystander suppression in which regulatory cytokines deviate the immune response towards a protective response. 6) The mechanisms underlying the initiation of the autoimmune response and antigen spreading are still undetermined. They could imply a direct abnormality of the target cell in the case of organ-specific autoimmune diseases (e.g. infection with a virus showing a selective tropism for the target cell in organ-specific autoimmune diseases, or loss of physiological regulation of major histocompatibility complex molecule expression) or could be consequence of a ubiquitous cell abnormality such as increased apoptosis in SLE. The respective roles of genetic and environmental factors in these triggering events remain to be determined.Keywords
This publication has 100 references indexed in Scilit:
- A Mechanism for the Major Histocompatibility Complex–linked Resistance to AutoimmunityThe Journal of Experimental Medicine, 1997
- Persistent GAD 65 Antibodies in Longstanding IDDM are not Associated with Residual Beta-Cell Function, Neuropathy or HLA-DR StatusHormone and Metabolic Research, 1997
- T cell Clones to Epitopes of Glutamic Acid Decarboxylase 65 Raised from Normal Subjects and Patients with Insulin-dependent DiabetesJournal of Autoimmunity, 1996
- Evidence for Somatic Mutation and Affinity Maturation of Diabetes Associated Human Autoantibodies to Glutamate DecarboxylaseJournal of Autoimmunity, 1996
- Peripheral T cell Clones from NOD Mice Specific for GAD65 Peptides: Lack of Islet Responsiveness or DiabetogenicityJournal of Autoimmunity, 1996
- Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouseInternational Immunology, 1995
- Natural autoantibodies: The other side of the immune systemResearch in Immunology, 1995
- Determinant spreading and the dynamics of the autoimmune T-cell repertoireImmunology Today, 1993
- The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodiesMolecular Neurobiology, 1991
- Transgenic Mice with I-A on Islet Cells Are Normoglycemic But Immunologically IntolerantScience, 1989